Ruxolitinib-loaded black phosphorus nanosheets actively target proximal tubule cells to ameliorate nephrotic syndrome by reducing inflammation and oxidative stress
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Pregnancy and preeclampsia studies · Neurological Complications and Syndromes · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Nephrotic syndrome10.1016/j.pcl.2018.08.006 ↗
2. Nephrotic syndrome10.1016/j.pop.2020.08.002 ↗
3. Nephrotic syndrome in infants and children: pathophysiology and management10.1080/20469047.2017.1374003 ↗
4. Idiopathic nephrotic syndrome in children10.1016/S0140-6736(18)30536-1 ↗
5. Nephrotic syndrome in adults
6. Pediatric nephrotic syndrome: pharmacologic and nutrition management10.1002/ncp.10622 ↗
7. Congenital nephrotic syndrome10.1038/s41372-021-01279-0 ↗
8. Nephrotic syndrome10.1542/pir.2020-001230 ↗
9. National Kidney Foundation of Michigan, Merck, 〈http://www.merck.com/mmpe/sec17/ch233/ch233c.html〉.
10. Chronic kidney disease in children10.1093/ckj/sfw047 ↗
11. The nephrotic syndrome is an immunoinflammatory disorder10.1016/j.mehy.2006.04.072 ↗
12. Oxidant stress in primary nephrotic syndrome: does it modulate the response to corticosteroids?10.1007/s00467-009-1246-2 ↗
13. Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change10.1111/j.1523-1755.2005.00386.x ↗
14. Reactive oxygen species: drivers of physiological and pathological processes10.2147/JIR.S275595 ↗
15. Reactive oxygen species in metabolic and inflammatory signaling10.1161/CIRCRESAHA.117.311401 ↗
16. Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria10.1203/PDR.0b013e318186ddb2 ↗
17. The nephrotic syndrome is an immunoinflammatory disorder10.1016/j.mehy.2006.04.072 ↗
18. Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings10.1007/s00467-018-3994-3 ↗
19. Predictors of remission and relapse in idiopathic nephrotic syndrome: a prospective cohort study10.1007/s00467-013-2736-9 ↗
20. Revised guidelines for management of steroid-sensitive nephrotic syndrome10.4103/0971-4065.41289 ↗
21. Nephrotic syndrome: updates and approaches to treatment10.1007/s40746-016-0044-x ↗
22. Reducing steroids in relapsing nephrotic syndrome: the restern study-protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study10.1136/bmjopen-2017-018148 ↗
23. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence10.1080/10428194.2016.1195501 ↗
24. Ruxolitinib in myelofibrosis and polycythemia vera
25. Untwining anti-tumor and immunosuppressive effects of JAK inhibitors-a strategy for hematological malignancies?10.3390/cancers13112611 ↗
26. Ruxolitinib for the treatment of essential thrombocythemia10.1097/HS9.0000000000000056 ↗
27. Biodegradable black phosphorus-based nanomaterials in biomedicine: theranostic applications10.2174/0929867324666170920152529 ↗
28. 2D black phosphorus-based biomedical applications10.1002/adfm.201808306 ↗
29. Black phosphorus nanosheets as a robust delivery platform for cancer theranostics10.1002/adma.201603276 ↗
30. Recent advances on black phosphorus for biomedicine and biosensing10.1002/adfm.201900318 ↗
31. Black phosphorus, an emerging versatile nanoplatform for cancer immunotherapy10.3390/pharmaceutics13091344 ↗
32. Current advances in black phosphorus-based drug delivery systems for cancer therapy10.1002/advs.202003033 ↗
33. Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer
34. Treating acute kidney injury with antioxidative black phosphorus nanosheets10.1021/acs.nanolett.9b05218 ↗
35. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery10.1021/bc300020f ↗
36. Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation10.1016/j.tox.2017.01.007 ↗
37. d (-)-salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models10.1016/j.intimp.2015.04.016 ↗
38. Quercetin and quercitrin attenuates the inflammatory response and oxidative stress in LPS-induced RAW264.7 cells: in vitro assessment and a theoretical model10.1155/2019/7039802 ↗
39. l-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats10.1111/j.1440-1797.2006.00592.x ↗
40. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation10.1016/j.biopha.2021.111308 ↗
41. Doxorubicin-induced alterations in kidney functioning, oxidative stress, DNA damage, and renal tissue morphology; improvement by acacia hydaspica tannin-rich ethyl acetate fraction10.1016/j.sjbs.2020.07.011 ↗
42. Regulation of iNOS on immune cells and its role in diseases10.3390/ijms19123805 ↗
43. Role of nitric oxide in inflammatory diseases10.1007/s10787-007-0013-x ↗
44. Anti-inflammatory effect of mangostenone F in lipopolysaccharide-stimulated RAW264.7 macrophages by suppressing NF-κB and MAPK activation10.4062/biomolther.2014.052 ↗
45. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis10.1111/j.1440-1797.2010.01383.x ↗
46. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease10.1038/ki.1986.28 ↗
47. Liquid exfoliation of solvent-stabilized few-layer black phosphorus for applications beyond electronics10.1038/ncomms9563 ↗
48. A novel strategy for liquid exfoliation of ultrathin black phosphorus nanosheets10.1166/jbn.2020.2909 ↗
49. Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer
50. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine10.1039/D0CS01127D ↗
51. Surface-bound reactive oxygen species generating nanozymes for selective antibacterial action10.1038/s41467-021-20965-3 ↗
52. JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin10.1186/1476-9255-5-7 ↗
53. Mechanisms of H2O2-induced oxidative stress in endothelial cells exposed to physiologic shear stress10.1097/01.mat.0000247157.84350.e8 ↗
54. 2',7'-Dichlorofluorescein (DCF) or 2',7'-dichlorodihydrofluorescein diacetate (DCFH2-DA) to measure reactive oxygen species in erythrocytes10.1016/j.biopha.2021.111512 ↗
55. Blood-contacting biomaterials: in vitro evaluation of the hemocompatibility10.3389/fbioe.2018.00099 ↗
56. Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease10.1159/000447649 ↗
57. Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis10.1111/j.1365-2362.2005.01488.x ↗